AlphAIAlphAI — Financial news for AI agents
investing.comOCT 211 min read$BDN

Brandywine earnings beat by $0.04, revenue topped estimates

Brandywine (BDN) reported Q3 EPS of -$0.13, beating estimates by $0.04, with revenue of $125.64M, topping expectations. Shares closed at $2.73, down 13.88% over 3 months. InvestingPro rates its financial health as 'fair performance'.

Original reporting
investing.com
Published Oct 21, 2026, 8:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BDN
Bullish
high confidence
Mentioned
$BDN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BDNBullishMed
01

Why it matters

Earnings beat may trigger short covering and modest buying, but the overall negative earnings and weak guidance keep risk elevated.

02

Market read

The earnings surprise provides a short‑term trading opportunity for BDN, though broader market impact is minimal.

03

What to watch

No guidance was provided and the company still posted a loss; cash burn concerns could limit upside.

Relevance 7/10Novelty 8/10Timing: post‑market after earnings release

Background

Brandywine (NYSE: BDN) is a small‑cap biotech firm that recently posted a loss but beat consensus estimates for Q3.

Company-level read

Ticker impact

$BDNBullishHigh confidence
Context

Brandywine reported Q3 EPS of -$0.13 beating estimates by $0.04 and revenue of $125.64M above the $110.85M consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat is modest but better than expectations; investors may bid the stock higher in after‑hours trading.

Market effects

Sector

Small‑cap biotech sector may see slight rally on positive earnings surprise.

Regional

U.S. market participants may adjust exposure to niche biotech stocks.

Global

Limited; impact confined to niche investors.

Counterpoint

What could challenge this read

The beat is modest and the stock remains down sharply YTD; price may stay pressured despite the surprise.

Key entities

  • company
    Brandywine

    Biotech firm reporting Q3 results.

Read at source← All news

StoryBrandywine Realty Trust revises 2026 loss per share and Core FFO guidance

Also covered by

2 outlets

Related articles

OCT 21
$BDNMed

A real estate company now expects a 62–64¢ loss per share in 2026

Brandywine Realty Trust (BDN) reported a Q3 2026 net loss of $0.13 per share, including impairment charges and debt extinguishment losses. Core FFO was $0.14 per share. The company adjusted its 2026 loss per share guidance to $0.62–$0.64. Portfolio occupancy was 89.0% leased, with mixed NOI results. BDN completed several property sales and debt repayments, and repurchased shares. 2026 guidance includes assumptions on occupancy, leasing, and financial activities.

stocktitan.net2 min
OCT 6
$BDNLow

BRANDYWINE REALTY TRUST (BDN): Completion of Acquisition or Disposition of Assets

BRANDYWINE REALTY TRUST (BDN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Brandywine Realty Trust Unaudited Pro Forma Consolidated Financial Statements The pro forma consolidated balance sheet for Brandywine Realty Trust (the “Company, “we” or “us”) as of June 30, 2026 has been prepared as if the significant disposition of the property located at 3151

SEC EDGAR 8-K2 min